ADDITIONAL MATERIAL

SUPPLEMENTARY FIGURES





Figure S1. Kaplan Meier plots for progression-free survival (PFS) in the two cohorts (responders and non-responders) of CRC patients. The plots show a significantly different profile in responder versus non-responder patients.



^{1 =} previously undetected mutations

Figure S2. Frequencies of mutation in the six genes correlated with anti-EGFR moAb responsiveness. The figure shows the mutations detected in genes (NRAS, BRAF, PIK3CA, FBXW7, SMAD4 and previously undetected variations at KRAS,) that display imbalanced frequencies in responder versus non-responder patients.

CR = Complete remission PR = Partial response SD = Stable disease PD = Progressive disease




Figure S3. Sanger sequencing validation of *BRAF, NRAS***, and** *FBXW7* **mutations.** All mutations found in *BRAF, NRAS*, and *FBXW7* were validated with Sanger sequencing. The figure shows one representative sample for each gene. On the left are displayed Sanger chromatograms, while results of NGS, showing read alignment to the reference genome, are on the right of the panel.